Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 9742
Conférences

le (22m11s)

Technique, research and benefits

Interface technology/clinical/SHS/public health : case study interventional radiology  >> Jean PalussièreRadiology in oncology or so called interventional oncology is now considered by certain as the fourth oncological discipline, alongside surgical, radiation, and medical oncology. This makes it particularly dynamic and it is important for interventional radiologists to stay on top of technological developments. During the last ten years the therapeutic part of Interventional Oncology has rapidly grown in different fields such as thermal ablation and local drug delivery. Thermal ablation, which allows to treat tumors with temperature modifications, has known an increasing development during the last 10 years ...
Voir la vidéo
Conférences

le (18m29s)

Sociology contribution to understanding the (no)diffusion of a medical innovation

Interface technology/clinical/SHS/public health : case study interventional radiology We will present results of an undergoing study on the socioeconomic processes of recognition in oncology of a long-standing medical innovation, the so-called interventional radiology (IR). This project is conducted by a multidisciplinary team gathering health sociologist, sociologist of science, economist of innovation, health lawyer and interventional radiologist, supported by INCa. With scientometrics and patent landscaping, we get an understanding of the IR discoveries’ chronology and identify the relationships established between science, medicine and industry. Through field observations and semi-directed interviews, we analyzed the strategies of legitimation of IR, seeking ...
Voir la vidéo
Conférences

le (19m21s)

Cost-effectiveness analysis for decision making, illustrated theory

Interface technology/clinical/SHS/public health : case study interventional radiologyIn a health care system with limited resources, each euro invested in a health care intervention is no longer available for another intervention. This imposes the need for a prioritization of health care interventions according to their additional value for money for maximizing health at a given cost. Cost-effectiveness analyses may answer two main questions: 1) does an intervention present sufficient value for money to be funded within a health system? The decision is based on the absolute value of the incremental cost-effectiveness ratio; 2) is further research needed to inform the decision ...
Voir la vidéo
Conférences

le (9m11s)

Innovation reimbursement

Interface technology/clinical/SHS/public health : case study interventional radiology Novel diagnostic and therapeutic strategies is a continuum of 3 strongly associated phases : clinical research, medico-economic evaluation of a novel strategy and deployment of innovation, the last one being a field of competence of centers of expertise such as SIRIC BRIO.In the full cycle of innovation, the money time is the major challenge of a large deployment. The main problem is to find money. But, in 2015, 3 changes should improve the innovation continuum. Should it be a progress, an obstacle, or both ?...Cette présentation a été donnée dans ...
Voir la vidéo
Conférences

le (15m1s)

Standardizing G8 evaluation

Non-pharmaceutical innovations and public healthManagement of the frail elderly with cancer is a challenge. Beside a poor outcome as compared to younger subjects, physicians will face increased risk of treatment-induced toxicity but also unexpected adverse events because of the underlying comorbidities and potential major consequences of these toxicities on the outcome because of frailty. In depth evaluation of the patient through geriatric assessment has been demonstrated as predictive of these adverse events but is time-consuming so that only a minority of cancer treatment hospitals will be able to propose it. Screening is part of the solution and G8 one of ...
Voir la vidéo
Conférences

le (19m53s)

Curing leukemia ?

Non-pharmaceutical medical innovations and public healthThe use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about long-term safety, medication adherence and healthcare costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses, a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms ...
Voir la vidéo
Conférences

le (29m17s)

Translational cancer genomics and proteomics

Translational science : how to move from biology to clinical applicationsEvaluation of cell-free DNA (cfDNA) is a very attractive tool to serve as “liquid biopsy” to define and establish mutational changes in circulating tumor DNA (ctDNA) during cancer therapy.To identify tumor specific mutations in serum ctDNA associated with resistance against tamoxifen in metastatic breast cancer.Ten ER-positive metastatic breast cancer patients treated with first-line tamoxifen with blood sera available at start therapy (S1), during treatment (S2) and at disease progression (S3) were selected. DNA from normal and primary tumor tissue and cfDNA from sera were sequenced using the Ion Torrent Personal ...
Voir la vidéo
Conférences

le (13m9s)

Multisarc

Translational science : how to move from biology to clinical applications Soft-tissues sarcomas represent an heterogeneous group of tumors. Stadard of care is surgical resection followed by radiotherapy. Patients with metastatic relapse are treated with chemotherapy but the overall survival is only approximatly 18 months. Actual research try to define new therapeutic targets, adapted to the type of sarcoma. The personalized medicine project aims to propose to patients with advanced sarcoma a targeted therapy based on the genomic and immunilogical profile. The main difference with other projects resides in ...
Voir la vidéo
Conférences

le (18m24s)

A new preclinical model to test the response of breast cancer to genomically targeted therapy

Translational science : how to move from biology to clinical applicationsThe rapid progress in next generation DNA sequencing technology (NGS) means it is now possible, in principle, to obtain a complete list of the genetic abnormalities in a tumour. In practice, clinicians use NGS to obtain a much shorter list of "actionable" mutations that can be targeted with available drugs or used as prognostic markers. Unfortunately, the mere presence of an actionable mutation does not guarantee a response to the cognate drug, as shown by the SAFIR1 study (André et al 2014). To spare patients unnecessary exposure to experimental drugs, ...
Voir la vidéo
Conférences

le (16m55s)

Bordeaux Cancer Initiative

Translational science : how to move from biology to clinical applicationsUpon request of the University, the SIRIC was mandated to develop a transversal cancer axis at the University. The axis development was led by BRIO management team along with a committee representing various disciplines within the University having an interest for cancer research. The axis definition focused on cancer research complementary to the SIRIC BRIO and is based mostly on basic and technological research. Five programmes are part of the axis: interaction radiation/living beings, nanotechnologies and innovations, tumor microenvironment, risk and predictions, cell remodelling. 150 scientists from 27 Bordeaux institutes ...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte